BioAge Announces PositiveInterimPhase 1Data for BGE-102, a Novel Brain-Penetrant NLRP3Inhibitor... BGE-102 achieved 90-98% suppression of IL-1β, a cytokine directly downstream of NLRP3, at Day 14 ... Background on BGE-102 and NLRP3.
Selective Degradation of NIMA-related kinase 7 (NEK7) via a MolecularGlue Degrader Inhibits IL-1Downstream of NLRP3 Inflammasome Activation ...Introduction to NEK7 in NLRP3 Inflammasome Activation ... NLRP3 ... Activation of the NLRP3. NLRP3 NEK7. NLRP3 ... NLRP3.
In March 2024, Parkinson’s UK announced the investment of GBP2.1 million to support Neumora Therapeutics to carry out preclinical testing of NMRA-NLRP3, a NLRP3 inhibitor with the potential to ...
DelveInsight’s “NLRP3 Protein InhibitorsPipelineInsight 2025” report provides comprehensive insights about 20+ companies and 25+ pipeline drugs in the NLRP3 Protein Inhibitors pipeline landscape ... NLRP3 Protein Inhibitors Overview.